naMitecan
- CAS No.
- 372105-27-6
- Chemical Name:
- naMitecan
- Synonyms
- ST-1968;naMitecan;1H-Pyrano[3',4':6,7]indolizino[1,2-b]quinoline-11-carboxaldehyde, 4-ethyl-3,4,12,14-tetrahydro-4-hydroxy-3,14-dioxo-, 11-[O-(2-aminoethyl)oxime], [C(E),4S]-
- CBNumber:
- CB12628184
- Molecular Formula:
- C23H22N4O5
- Molecular Weight:
- 434.44458
- MDL Number:
- MFCD19443712
- MOL File:
- 372105-27-6.mol
- MSDS File:
- SDS
| Product description | Number | Pack Size | Price |
| Namitecan | XPA10527 | 5mg | $1413 |
| Namitecan | XPA10527 | 10mg | $2260.8 |
| Namitecan | XPA10527 | 25mg | $4239.25 |
| Namitecan | XPA10527 | 50mg | $6782.5 |
| Namitecan 98.03% | CS-6708 | 5mg | $542 |
| Boiling point | 835.2±75.0 °C(Predicted) |
|---|---|
| Density | 1.51±0.1 g/cm3(Predicted) |
| storage temp. | Store at -20°C |
| solubility | DMSO: 250 mg/mL (575.45 mM) |
| form | Solid |
| pka | 11.20±0.20(Predicted) |
| color | Light yellow to yellow |
| FDA UNII | X34Z8N66T3 |
naMitecan price
| Manufacturer | Product number | Product description | CAS number | Packaging | Price | Updated | Buy |
|---|---|---|---|---|---|---|---|
| Biosynth | XPA10527 | Namitecan | 372105-27-6 | 5mg | $1413 | 2026-06-05 | Buy |
| Biosynth | XPA10527 | Namitecan | 372105-27-6 | 10mg | $2260.8 | 2026-06-05 | Buy |
| Biosynth | XPA10527 | Namitecan | 372105-27-6 | 25mg | $4239.25 | 2026-06-05 | Buy |
| Biosynth | XPA10527 | Namitecan | 372105-27-6 | 50mg | $6782.5 | 2026-06-05 | Buy |
| ChemScene | CS-6708 | Namitecan 98.03% | 372105-27-6 | 5mg | $542 | 2026-06-04 | Buy |
naMitecan Chemical Properties,Uses,Production
Uses
Namitecan is a potent topoisomerase I inhibitor, with antitumor property.
in vivo
Namitecan (10 mg/kg) in combination with cetuximab (1 mg/mouse) induces synergistic antitumor effects in SCC models as a function of EGFR gene copy number[1]. ST1968 (25 mg/kg) causes acceptable body weight loss and no toxic deaths. ST1968 produces a 100% complete response rate in the mice bearing the A431 tumor, and retains a relevant activity in the topotecan-resistant tumor[2].
IC 50
Topoisomerase I
References
[1] De Cesare M, et al. Synergistic antitumor activity of cetuximab and namitecan in human squamous cell carcinoma models relies on cooperative inhibition of EGFR expression and depends on high EGFR gene copy number. Clin Cancer Res. 2014 Feb 15;20(4):995-1006. DOI:10.1158/1078-0432.CCR-13-1684
[2] Zuco V, et al. Efficacy of ST1968 (namitecan) on a topotecan-resistant squamous cell carcinoma. Biochem Pharmacol. 2010 Feb 15;79(4):535-41. DOI:10.1016/j.bcp.2009.09.012
naMitecan Preparation Products And Raw materials
Raw materials
Preparation Products
naMitecan Suppliers
| Supplier | Tel | Country | ProdList | Advantage | |
|---|---|---|---|---|---|
| Shochem(Shanghai) Co.,Ltd | 86-21-50800795 | info@shochem.com | CHINA | 288 | 58 |
| TargetMol Chemicals Inc. | +1-781-999-5354; +1-00000000000 | marketing@targetmol.com | United States | 32468 | 58 |
| Aladdin Scientific | tp@aladdinsci.com | United States | 52923 | 58 | |
| BOC Sciences | 1-631-485-4226; 16314854226 | info@bocsci.com | United States | 9920 | 65 |
| ShangHai Caerulum Pharma Discovery Co., Ltd. | 18149758185 18149758185 | sales-cpd@caerulumpharma.com | China | 3504 | 58 |
| Shanghai YuanYe Biotechnology Co., Ltd. | 13636370518 | shyysw007@163.com | China | 89686 | 60 |
| Fan De(Beijing) Biotechnology Co., Ltd. | 15911056312 | liming@bio-fount.com | China | 9729 | 58 |
| Changzhou Chenhong Biotechnology Co., Ltd. | +86-0519-85788828 +86-13775037613 | sales@chemrenpharm.com | China | 4061 | 58 |
| ChemeGen(Shanghai) Biotechnology Co.,Ltd. | 18818260767 | sales@chemegen.com | China | 11218 | 58 |
| TargetMol Chemicals Inc. | 4008200310 15002144251 | marketing@tsbiochem.com | China | 24960 | 58 |
